Osimertinib Tablets 40 mg, 80 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 40 mg, 80 mg

Reference Brands: Tagrisso (USA/EU)

Category: Oncology Cancer Care

Osimertinib (40 mg, 80 mg tablets) is a third-generation EGFR inhibitor for non-small cell lung cancer with EGFR mutations, including the T790M resistance mutation, and as adjuvant therapy after surgery. It is made by AstraZeneca as Tagrisso. Supply is through authorised distribution or named-patient import; ask us which route fits your country.

Product Description:

Osimertinib is a third-generation EGFR inhibitor built to solve the problem that defeated the first generation. Tumours treated with gefitinib or erlotinib escape after about a year, most often by acquiring the T790M gatekeeper mutation, which blocks those drugs from binding. Osimertinib binds irreversibly and is active against T790M while sparing wild-type receptor, which is why it causes markedly less rash and diarrhoea than its predecessors despite greater potency.

It is now used first line in EGFR-mutant advanced non-small cell lung cancer rather than held in reserve, as adjuvant treatment after resection of EGFR-mutant disease, and after progression on earlier inhibitors in T790M-positive tumours. It penetrates the central nervous system well and controls brain metastases, a decisive advantage in this population. Diarrhoea, rash, paronychia and stomatitis are usually manageable; QT prolongation, reduced ejection fraction and rare interstitial lung disease need monitoring.

Sourcing notes. Originator product, on patent in the major markets, with two tablet strengths — the lower one exists for dose reduction, not as an alternative starting dose. EGFR mutation testing is mandatory at the destination. Oral solid, room temperature.